Vaccine to prevent Shigella infections in young children
Official title: O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis
Funded at University of Maryland Baltimore · NIH-11090367 · Data updated 2026-11-12
This study is testing a new vaccine designed to help protect young children under five from Shigella, a germ that causes bad diarrhea, to see if it can keep them healthy and safe from infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $910,903 |
| NIH project number | 5R01AI177142-03 |
| Project ID | NIH-11090367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0 to 5 years, particularly those living in areas with limited access to clean water and sanitation.
✕Less likely to help
Patients older than 5 years or those not at risk for Shigella infections may not benefit from this research.
What this research studies
This research focuses on developing a new vaccine to protect young children from Shigella, a bacteria that causes severe diarrhea and can lead to long-term health issues. The vaccine aims to target two specific strains of Shigella and uses a unique protein to enhance immune response. By conducting trials, the researchers will assess the vaccine's safety and effectiveness in preventing infections, particularly in children under five years old who are most at risk. The approach is innovative as it combines different components to create a more effective immune response against this serious pathogen.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of Shigella infections in young children, improving their health and quality of life.
How similar studies have gone: Previous research has shown promise in developing vaccines against Shigella, but this specific approach using the IpaB protein is novel and has not been extensively tested.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Pasetti, Marcela F — University of Maryland Baltimore
- Study coordinator: Pasetti, Marcela F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.